196 related articles for article (PubMed ID: 15569129)
1. Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.
Hällsten K; Virtanen KA; Lönnqvist F; Janatuinen T; Turiceanu M; Rönnemaa T; Viikari J; Lehtimäki T; Knuuti J; Nuutila P
Diabet Med; 2004 Dec; 21(12):1280-7. PubMed ID: 15569129
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin.
Viljanen AP; Virtanen KA; Järvisalo MJ; Hällsten K; Parkkola R; Rönnemaa T; Lönnqvist F; Iozzo P; Ferrannini E; Nuutila P
J Clin Endocrinol Metab; 2005 Dec; 90(12):6523-8. PubMed ID: 16189256
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study.
Lautamäki R; Airaksinen KE; Seppänen M; Toikka J; Luotolahti M; Ball E; Borra R; Härkönen R; Iozzo P; Stewart M; Knuuti J; Nuutila P
Diabetes; 2005 Sep; 54(9):2787-94. PubMed ID: 16123370
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
Virtanen KA; Hällsten K; Parkkola R; Janatuinen T; Lönnqvist F; Viljanen T; Rönnemaa T; Knuuti J; Huupponen R; Lönnroth P; Nuutila P
Diabetes; 2003 Feb; 52(2):283-90. PubMed ID: 12540598
[TBL] [Abstract][Full Text] [Related]
5. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.
Iozzo P; Hallsten K; Oikonen V; Virtanen KA; Parkkola R; Kemppainen J; Solin O; Lonnqvist F; Ferrannini E; Knuuti J; Nuutila P
Diabetes Care; 2003 Jul; 26(7):2069-74. PubMed ID: 12832315
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
Hällsten K; Virtanen KA; Lönnqvist F; Sipilä H; Oksanen A; Viljanen T; Rönnemaa T; Viikari J; Knuuti J; Nuutila P
Diabetes; 2002 Dec; 51(12):3479-85. PubMed ID: 12453903
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
Juurinen L; Kotronen A; Granér M; Yki-Järvinen H
J Clin Endocrinol Metab; 2008 Jan; 93(1):118-24. PubMed ID: 17956948
[TBL] [Abstract][Full Text] [Related]
8. Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPARγ agonist.
Badeau RM; Honka MJ; Lautamäki R; Stewart M; Kangas AJ; Soininen P; Ala-Korpela M; Nuutila P
Ann Med; 2014 Feb; 46(1):18-23. PubMed ID: 24266715
[TBL] [Abstract][Full Text] [Related]
9. Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus.
Borra R; Lautamäki R; Parkkola R; Komu M; Sijens PE; Hällsten K; Bergman J; Iozzo P; Nuutila P
Metabolism; 2008 Oct; 57(10):1445-51. PubMed ID: 18803951
[TBL] [Abstract][Full Text] [Related]
10. Metformin treatment significantly enhances intestinal glucose uptake in patients with type 2 diabetes: Results from a randomized clinical trial.
Koffert JP; Mikkola K; Virtanen KA; Andersson AD; Faxius L; Hällsten K; Heglind M; Guiducci L; Pham T; Silvola JMU; Virta J; Eriksson O; Kauhanen SP; Saraste A; Enerbäck S; Iozzo P; Parkkola R; Gomez MF; Nuutila P
Diabetes Res Clin Pract; 2017 Sep; 131():208-216. PubMed ID: 28778047
[TBL] [Abstract][Full Text] [Related]
11. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
Tiikkainen M; Häkkinen AM; Korsheninnikova E; Nyman T; Mäkimattila S; Yki-Järvinen H
Diabetes; 2004 Aug; 53(8):2169-76. PubMed ID: 15277403
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
van der Meer RW; Rijzewijk LJ; de Jong HW; Lamb HJ; Lubberink M; Romijn JA; Bax JJ; de Roos A; Kamp O; Paulus WJ; Heine RJ; Lammertsma AA; Smit JW; Diamant M
Circulation; 2009 Apr; 119(15):2069-77. PubMed ID: 19349323
[TBL] [Abstract][Full Text] [Related]
13. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
[TBL] [Abstract][Full Text] [Related]
14. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
15. Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.
Karlsson HK; Hällsten K; Björnholm M; Tsuchida H; Chibalin AV; Virtanen KA; Heinonen OJ; Lönnqvist F; Nuutila P; Zierath JR
Diabetes; 2005 May; 54(5):1459-67. PubMed ID: 15855334
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
17. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial.
van Wijk JP; de Koning EJ; Cabezas MC; op't Roodt J; Joven J; Rabelink TJ; Hoepelman AI
Ann Intern Med; 2005 Sep; 143(5):337-46. PubMed ID: 16144892
[TBL] [Abstract][Full Text] [Related]
18. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
Miyazaki Y; Glass L; Triplitt C; Matsuda M; Cusi K; Mahankali A; Mahankali S; Mandarino LJ; DeFronzo RA
Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
